ATE212129T1 - Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle - Google Patents

Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle

Info

Publication number
ATE212129T1
ATE212129T1 AT95941326T AT95941326T ATE212129T1 AT E212129 T1 ATE212129 T1 AT E212129T1 AT 95941326 T AT95941326 T AT 95941326T AT 95941326 T AT95941326 T AT 95941326T AT E212129 T1 ATE212129 T1 AT E212129T1
Authority
AT
Austria
Prior art keywords
methods
antigens
lam
cells
presented
Prior art date
Application number
AT95941326T
Other languages
English (en)
Inventor
Robert L Modlin
Peter A Sieling
Michael B Brenner
Patrick J Brennan
Steven A Porcelli
Stephen T Furlong
Original Assignee
Brigham & Womens Hospital
Univ California Los Angeles
Univ Colorado State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/322,980 external-priority patent/US5679347A/en
Priority claimed from US08/322,979 external-priority patent/US5853737A/en
Priority claimed from US08/501,600 external-priority patent/US6238676B1/en
Application filed by Brigham & Womens Hospital, Univ California Los Angeles, Univ Colorado State Res Found filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE212129T1 publication Critical patent/ATE212129T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95941326T 1994-10-13 1995-10-13 Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle ATE212129T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/322,980 US5679347A (en) 1992-12-10 1994-10-13 Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
US08/322,979 US5853737A (en) 1992-12-10 1994-10-13 Method for inducing a CD1-restricted immune response
US50149195A 1995-07-12 1995-07-12
US08/501,600 US6238676B1 (en) 1992-12-10 1995-07-12 Presentation of hydrophobic antigens to T-cells by CD1 molecules
PCT/US1995/013274 WO1996012190A2 (en) 1994-10-13 1995-10-13 Presentation of hydrophobic antigens to t-cells by cd1 molecules

Publications (1)

Publication Number Publication Date
ATE212129T1 true ATE212129T1 (de) 2002-02-15

Family

ID=27502254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941326T ATE212129T1 (de) 1994-10-13 1995-10-13 Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle

Country Status (7)

Country Link
EP (2) EP1170592A1 (de)
JP (1) JPH10510142A (de)
AT (1) ATE212129T1 (de)
AU (1) AU694299B2 (de)
CA (1) CA2202680A1 (de)
DE (1) DE69525058D1 (de)
WO (1) WO1996012190A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
EP0755517B1 (de) 1994-04-14 1999-12-01 Adcock Ingram Limited Verfahren zum nachweis der gegenwart einer mykobakterien-spezies und testsatz sowie antikörpes zur verwendung in diesem verfahren
AU749218C (en) * 1997-09-12 2003-10-30 Brigham And Women's Hospital Synthetic antigens for CD1-restricted immune responses
JP2002511421A (ja) * 1998-04-13 2002-04-16 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド Ｃｄ−１抗原およびｔ細胞刺激化合物を含むワクチン組成物およびその使用方法
AU2002213588A1 (en) * 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
FR2819724B1 (fr) * 2001-01-22 2005-05-13 Inst Necker Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
US7253159B2 (en) 2003-04-18 2007-08-07 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation using CD1 antigens
GB0708874D0 (en) * 2007-05-08 2007-06-13 Univ The Of Birmingham Assay for detecting mycrobacterial infection
EP3833743B1 (de) 2018-08-08 2024-01-24 NantBio, Inc. Rekombinante cd1-beschränkte t-zellen zur behandlung von tuberkulose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1423892A (en) * 1991-02-12 1992-09-07 Colorado State University Research Foundation Monoclonal antibodies directed towards mycobacterial antigens
AU1564592A (en) * 1991-02-12 1992-09-07 Dynagen, Inc. Agglutination test for mycobacterial antigens in biological samples
EP0751780B1 (de) * 1993-06-21 2003-09-03 Brigham And Women's Hospital Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien

Also Published As

Publication number Publication date
EP1170592A1 (de) 2002-01-09
EP0786088A2 (de) 1997-07-30
EP0786088B1 (de) 2002-01-16
AU694299B2 (en) 1998-07-16
DE69525058D1 (de) 2002-02-21
JPH10510142A (ja) 1998-10-06
WO1996012190A3 (en) 1996-06-27
AU4277996A (en) 1996-05-06
WO1996012190A2 (en) 1996-04-25
CA2202680A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
ES2109254T3 (es) Proteinas antigenas y vacunas que las contienen para la prevencion de cocidiosis.
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
ES2116719T3 (es) Dispositivo de analisis de flujo interrumpido.
FI913560A0 (fi) Syntetiska peptider, speciellt foer observation av hcv-anti-kroppar, hcv-infektionsdiagnos och dess foerhindrande sm vaccin.
ATE212129T1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
ES2176347T3 (es) Modulacion de la respuesta inmune.
DK199779A (da) Renset antigen til undersoegelse for neisseria gonorrhoeae antistoffer
ATE199184T1 (de) Testverfahren
ATE445839T1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
DK0751780T3 (da) Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder
KR930008462A (ko) 치주질환과 관련된 미생물의 검증방법에서 높은 pH에서의 추출로 단백질을 보호하는 용도 및 이에 유용한 키트
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
HUP0100130A2 (hu) Rekombináns Mycoplasma hyopneumoniae vakcina
DE60327544D1 (de) Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DK142488D0 (da) Treponema hyodysenteriae antigener, vaccine indeholdende disse antigener eller fragmenter deraf og metode til bestemmelse af antistoffer over for treponema hyodysenteriae
ATE114818T1 (de) Immuntest zum nachweis von alpha-haloacetamiden.
BR9105983A (pt) Anticorpos monoclonais que diferenciam entre proteinas de sequencias nativa e modificada
BR9503451A (pt) Processo de preparação de um antígeno derivado de um mocroorganismo causador de doença infecciosa e/ou parasitária processo de preparação de um antígeno de T cruzi antígeno derivado de midroorganismo causador de doença infecciosa e/ou parasitária antígeno derivado de T cruzi causador de doença de chagas composição a base de um antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária composição a base de antígeno de T cruzi utilização do antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária em testes sorológicos e vacinas utilização de antigeno derivado de T cruzi causador de doença de chagas em teste sorológico e vacinas processo para detecção de anticorpos anti antigeno de microorganismo causador de doença infecciosa e/ou parasitária e kit para sorodiagnóstico confirmatório para doença infecciosa e/ou parasitária
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties